DK200801600A - Method for treatment of inflammatory diseases - Google Patents
Method for treatment of inflammatory diseases Download PDFInfo
- Publication number
- DK200801600A DK200801600A DKPA200801600A DKPA200801600A DK200801600A DK 200801600 A DK200801600 A DK 200801600A DK PA200801600 A DKPA200801600 A DK PA200801600A DK PA200801600 A DKPA200801600 A DK PA200801600A DK 200801600 A DK200801600 A DK 200801600A
- Authority
- DK
- Denmark
- Prior art keywords
- compounds
- mentioned
- dermatitis
- diabetes
- induce
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (25)
1. Method of preventing or treating inflammatory disorders by administration of compounds which can induce a contact dermatitis. This method can be used in the prophylaxis or therapy of prediabetes or diabetes.
2. Method of preventing or treating inflammatory disorders by administration of compounds which can induce a contact dermatitis. This method can be used in the prophylaxis or therapy of celiac disease, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, ulcerative colitis, multiple sclerosis, hyperthyroidism, hypothyroidism, Hashimoto's thyroiditis, arteriosclerosis, myocardie infarction, psoriasis, parapsoriasis, pemphigus, lupus and/or associated complications in an individual.
3. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) by administration of compounds which induce an immune mediated dermatitis. Molecules according to claim 1 which can induce an immune mediated contact dermatitis, and can be used for the treatment or prevention of inflammatory disorders are characterized by the molecular formulas: C6-H8-N2 and C6-H3-C1-N2-04. Respectively 1,4-phenylenediamine (PPD) and 2,4-dinitro-1-chlorobenzene (DNCB), and derivates of PPD such as Bandrowski's base, 1,4-benzoquinone, 4-nitro-o-phenylenediamine, 2-chloro-p-phenylenediamine, 4-chloro-o-phenylenediamine, and 2-nitro-p-phenylenediamine.
4. Compounds according to claim 1-2 with the ability to induce an immune mediated dermatitis, which may have the same effect on inflammation: 2,4-dinitro-l-fluorobenzene (DNFB), 2,4,6-trinitrochlorohenzene (TNCB), 4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (oxazolone), 5-chloro-2-methyl-4-isothiazolin-3-one, 4-amino-3-nitrophenol, 3-nitro-p-hydroxyethylamino-phenol (4-i(2-Hydroxyethyl)amino)-3-nitrophcnol). resorcinol (1,3-Benzenediol), toluene-2,5-diamine (2,5-Diaminotoluene), and toluene-2,5-diaminesulfate (2,5-Diaminotoluene sulphate).
5. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) characterized by administration of compounds which can induce dermatitis and which have previously been used in the treatment of alopecia areata: 2,3-Diphenylcyclopropenone (DPCP), 3,4-Dibutoxy-3-cyclobutene-l,2-dione (squaric acid dibutyl ester), and triethyleneiminobenzoquinone (trenimon or triaziquone).
6. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) characterized by administration of compounds which can induce irritative dermatitis. These compounds are non-specific irritants which can cause an irritant contact dermatitis: Dithranoi (anthralin) and croton oil.
7. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) characterized by administration of compounds which act as inducers of dermatitis (as mentioned in claim no 2-5) and their derivate compounds with the following types of side chains: Hydroxyl (R-OH), Aldehyde (R-CHO), Carboxyl (R-COOH), Amine (R-NH2), Azide (R-N3), Cyanate (R-OCN), Isocyanide (R-NC), Isocyanate R-NCO, Isothiocyanate (R-NCS), Nitrile (R-CN), Nitrosooxy (R-ONO), Nitro (R-N02), Nitroso (R-NO), Pyridyl (R-C5H4N), Sulfo (R-SO3H), Sulfhydryl (R-SH), Thiocyanate (R-SCN), Benzyl (R-CFTC^Hs), Phenyl (R- C6H5), Haloformyl (R-COX), Methyl (R-CH3), Ethyl (R-CH2CH3), Propyl (R-CH2CH2CH3), Isopropyl (R-CH(CH3)2), Butyl (R-CH2CH2CH2CH3), Isobutyl (R-C(CH3)3) and Halo (R-X)
8. Method of preventing or treating inflammatory disorders in an individual (as mentioned in claim no 1) characterized by administration of all compounds which induce dermatitis. .
9. Compounds according to claims 1-8 characterized that the use is for the prophylaxis or therapy of inflammatory disorders by inducing a clinical or subclinical dermatitis in a certain but unspecific area of the body in order to induce a condition which by immune or other mechanisms oppose the development of the mentioned diseases.
10. The typical places of topical application of the reagents mentioned in claims 1-8, are: The antebrachium (lower-arm), the upper-arm, the wrist, the hands, the chest, the back, the neck, behind the ears, the femura region, the lower legs, or the feet.
11. All other places on the body, including the mouth or other body cavities are to be considered areas for application for the reagents mentioned in claim 1-8.
12. The reagent causing clinical or subclinical dermatitis (or the allergen), mentioned in claims 1-8, can also be administrated; perorally, intranasally, intrarectally, intravaginally, intradermally, subcutantneously, the outer ear or ear tract, or conjunctiva.
13. The reagent causing dermatitis (or the allergen) mentioned in claim 1-8 is to be applicated in an area from less than a droplet or injection area to an extented part of the body covering up to the total body area. A typical topical treatment area would be 1-9 cm2.
14. The reagent (or allergen) mentioned in claims 1-8, is to be applicated in water or in any buffer solution based on water, alcohols, aldehydes/ketones, fatty acids, or other fats implemented in pasta or cream.
15. The reagent (or allergen) mentioned in claims 1-8, is applicated directly as a fluid, as an ointment or using a spray, as a wash of product such as a soap, or can be emulsified or dissolved in a cream (e.g. petrolatum) and applicated in a chamber taped to the area. The reagent (or allergen) can also be emulsified or bound to a plaster, wristband, bracelet, sock, anklet, ring or other material which can be worn.
16. The reagent (or allergen) mentioned in claims 1-8, can be applicated in a tablet form or given as an injection or other deposit form.
17. Individuals to be treated with the compounds in claim 1-8, are patient at risk of or having inflammatory diseases, such as prediabetes or diabetes.
18. Prediabetes or diabetes, to be prevented or treated according to claim 17 are: Type 1 diabetes, Type 2 diabetes, MOODY, LADA, gestational diabetes, diabetes with characteristics of both type 1 and type 2 diabetes, and other forms of diabetes; furthermore prevention or treatment of diabetic complications or risk hereof, such as nurophatic nephropaty, retinophaty, or orther micro- or macrovascular disorders.
19. The individuals to be treated in accordance with claim 1-8 are persons having the risk of background population to develop diabetes; or any increased risk due to certain tissue types or other genetic markers, due to relatives with diabetes, due to presence of antibodies such as ICA anti-GAD, anti-IA2, anti-insulin, anti-C-transporter-protein, and/or cellular reactions against insulin-producing beta-cells or their components, due to laboratory or clinical tests indicating impaired glycaemic conditions.
20. Individuals to be treated with the compounds in claim 1-8, are patient at risk of or having inflammatory diseases, such as celiac disease, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, ulcerative colitis, multiple sclerosis, hyperthyroidism, hypothyroidism, Hashimoto's thyroiditis, arteriosclerosis, myocardic infarction, psoriasis, parapsoriasis, pemphigus, lupus and/or associated complications in an individual.
21. The individuals to be treated, are patients with inflammatory diseases (claim 20) which are in a preface, have the disease or have complications due to the disease
22. The individuals to be treated are persons having the risk of background population to develop an inflammatory disorder mentioned in claim 20, or any increased risk to develop any of these diseases due to certain tissue types, antibodies or other genetic markers, due to relatives with disease, due to presence of antibodies and/or cellular reactions.
23. Other diseases to consider for treatment are, atopic dermatitis, parasite infections, infections and other skin diseases.
24. Individuals to be treated with the compounds in claim 1-8, are patient at risk of or having cancer in the oesophagus, urine bladder, cervix uteri, pharynx, skin cancer, colon and/or rectum.
25. Individuals to be treated with the compounds in claim 1-8, are patient at risk of or having all other forms of cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801600A DK200801600A (en) | 2008-11-17 | 2008-11-17 | Method for treatment of inflammatory diseases |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200801600A DK200801600A (en) | 2008-11-17 | 2008-11-17 | Method for treatment of inflammatory diseases |
| DK200801600 | 2008-11-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200801600A true DK200801600A (en) | 2010-05-18 |
Family
ID=42227570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DKPA200801600A DK200801600A (en) | 2008-11-17 | 2008-11-17 | Method for treatment of inflammatory diseases |
Country Status (1)
| Country | Link |
|---|---|
| DK (1) | DK200801600A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015051458A1 (en) * | 2013-10-08 | 2015-04-16 | Lu qing-bin | Non-platimun-based anti-cancer compounds for use in targeted chemotherapy |
-
2008
- 2008-11-17 DK DKPA200801600A patent/DK200801600A/en not_active Application Discontinuation
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015051458A1 (en) * | 2013-10-08 | 2015-04-16 | Lu qing-bin | Non-platimun-based anti-cancer compounds for use in targeted chemotherapy |
| CN106232581A (en) * | 2013-10-08 | 2016-12-14 | 卢庆彬 | Non-platino anticancer compound for targeted chemotherapy |
| US10463662B2 (en) | 2013-10-08 | 2019-11-05 | Qing-Bin Lu | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy |
| CN114380700A (en) * | 2013-10-08 | 2022-04-22 | 卢庆彬 | Non-platinum based anti-cancer compounds for targeted chemotherapy |
| US11446294B2 (en) | 2013-10-08 | 2022-09-20 | Qing-Bin Lu | Non-platinum-based anti-cancer compounds for use in targeted chemotherapy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vala et al. | Medicinal benefits of coconut oil | |
| Provost et al. | Ethylenediamine contact dermatitis | |
| Verma et al. | Blastocystis hominis associated acute urticaria | |
| Xu et al. | Posttraumatic administration of luteolin protects mice from traumatic brain injury: implication of autophagy and inflammation | |
| Gong et al. | Acid-sensing ion channel 3 decreases phosphorylation of extracellular signal-regulated kinases and induces synoviocyte cell death by increasing intracellular calcium | |
| Li et al. | EPA and DHA inhibit endocytosis of claudin-4 and protect against deoxynivalenol-induced intestinal barrier dysfunction through PPARγ dependent and independent pathways in jejunal IPEC-J2 cells | |
| Unissa et al. | Psoriasis: a comprehensive review | |
| JP2006241080A (en) | Iv type allergy reaction inhibitor | |
| Meneghini et al. | Contact allergy to antirheumatic drugs. | |
| DK200801600A (en) | Method for treatment of inflammatory diseases | |
| KR20190008235A (en) | Carboxylic acids for treating / preventing skin diseases | |
| Fisher | Necrolytic acral erythema: a review of the literature | |
| Jimmy et al. | Aloe vera heals gastric ulcer in 7 days than omeprazole and cimetidine: prostaglandin | |
| Dhar et al. | Eczema and Dermatitis | |
| Maibach et al. | Vulvar dermatitis and fissures--irritant dermatitis from methyl benzethonium chloride. | |
| Zito et al. | 18553 Dermatologic foes faced by mixed martial arts fighters | |
| King et al. | Impaired autophagy following ex vivo cooling of simulated hypothermic temperatures in peripheral blood mononuclear cells from young and older adults | |
| JP2021504470A (en) | Composition for treating atopy or pruritus containing N-acetyl or N-acyl amino acid | |
| Sławińska et al. | 18512 The significance of dermoscopy and trichoscopy in differentiation of erythroderma due to various dermatologic disorders | |
| AU2017266729A1 (en) | Carboxylic acids for early childhood application | |
| US20140294988A1 (en) | Skin treatment formula for psoriasis | |
| Han et al. | Acute bullous irritant contact dermatitis caused by a Pulsatilla koreana extract | |
| Furau et al. | Effect of a Guaiazulene-Containing Ointment on Nipple and Areola Area Health of Women | |
| KR20180003553A (en) | At least one protease inhibitor for use in the prevention and / or treatment of skin lesions and a compound of at least one active ingredient | |
| Misra et al. | G191 (P) All that presents with spastic gait may not have cerebral palsy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |